Cere­nion to launch the C‑Trend® EEG Sta­tion in Europe

Con­tin­u­ous EEG is increas­ing­ly rec­om­mend­ed in clin­i­cal guide­lines for crit­i­cal­ly ill patients, includ­ing those after car­diac arrest, espe­cial­ly to detect seizures and sup­port neu­ro­log­i­cal out­come assess­ment. Yet in many hos­pi­tals, EEG mon­i­tor­ing remains dif­fi­cult to access due to lim­it­ed spe­cial­ist avail­abil­i­ty and com­plex work­flows.

C‑Trend EEG Sta­tion recent­ly released by Cere­nion is designed to change that.

By com­bin­ing AI-pow­ered EEG analy­sis, an easy-to-apply sin­gle-use elec­trode, and a com­plete bed­side work­sta­tion, C‑Trend EEG Sta­tion enables ICU teams to start mon­i­tor­ing brain activ­i­ty quick­ly, even when EEG spe­cial­ists are not imme­di­ate­ly avail­able. The sys­tem helps clin­i­cians observe brain func­tion trends, detect pat­terns such as seizures or burst sup­pres­sion, and sup­port faster diag­no­sis and treat­ment deci­sions direct­ly at the bed­side.

“Our goal has always been to make EEG mon­i­tor­ing acces­si­ble for every ICU team car­ing for crit­i­cal­ly ill patients. With C‑Trend EEG Sta­tion now avail­able in Europe, we are tak­ing an impor­tant step toward bring­ing prac­ti­cal, AI-sup­port­ed brain mon­i­tor­ing to the bed­side, help­ing clin­i­cians gain vis­i­bil­i­ty into brain func­tion when it mat­ters most,’ said Juk­ka Kor­te­lainen, CEO and co-founder of Cere­nion.

This launch is a sig­nif­i­cant mile­stone for the com­pa­ny, which believes that unveil­ing the secrets of the brain will enable bet­ter care for crit­i­cal­ly ill patients.

Read more about C‑Trend EEG Sta­tion and how it can sup­port brain mon­i­tor­ing in acute care: https://www.cerenion.com/product/

About Cere­nion

Cere­nion is a young med­ical device com­pa­ny with high ambi­tions, on a mis­sion to make EEG mon­i­tor­ing a rou­tine func­tion in acute health­care. The com­pa­ny is found­ed on years of research, and its roots lie deep in acad­e­mia. Cere­nion has offices in Oulu and Helsin­ki.

As a fore­run­ner of the field, the com­pa­ny is com­mit­ted to con­tin­u­ous research and devel­op­ment of nov­el prod­ucts that bring val­ue to the users and patients.

Con­tact per­son

Juk­ka Kor­te­lainen

PhD, CEO and Co-founder of Cere­nion

jukka.kortelainen@cerenion.com